만성폐쇄성폐질환(COPD) 치료제 시장 평가 : 유형별, 약제 등급별, 유통 채널별, 지역별 기회 및 예측(2018-2032년)

Global chronic obstructive pulmonary disease (COPD) treatment market is projected to witness a CAGR of 4.55% during the forecast period 2025-2032, growing from USD 22.31 billion in 2024 to USD 31.84 billion in 2032. The rapid expansion of the aging population, growing air pollution, and increasing popularity of smoking are some of the major factors bolstering the global chronic obstructive pulmonary disease (COPD) treatment market demand. The condition usually involves both emphysema and bronchitis and is known for affecting millions of individuals across the globe. The treatment for COPD usually involves corticosteroids and inhaled bronchodilators, among other therapies that improve the patients' quality of life and respiratory functioning. The treatment plans often integrate various pharmacologic and non-pharmacologic interventions.

The rapid expansion of the aging population also supports the market's growth. As per the estimates of the World Health Organization (WHO), one in six people across the globe will be sixty or older by 2030. This growth is bolstering the demand for the global chronic obstructive pulmonary disease (COPD) treatment market as the prevalence of the condition is two to three times higher in individuals over the age of sixty than in individuals from younger age groups. Furthermore, rising investments focused on patient adherence technologies, digital therapeutics, and advanced therapeutic approaches, coupled with an increasing number of biopharmaceutical companies working on personalized COPD treatment, also provide lucrative growth opportunities to the market.

Additionally, the dedicated efforts by the market's key players to ensure the availability of innovative solutions for treating and managing COPD also provide lucrative growth opportunities to the COPD treatment market. In May 2024, AstraZeneca PLC unveiled its latest research on immune-mediated and respiratory diseases at the American Thoracic Society (ATS) International Conference 2024. Meanwhile, healthcare organizations and government institutions across the globe are working on increasing awareness about COPD and the availability of different treatment solutions to address the growing threat of the disease and improve patient access to innovative therapies.

Increasing Approvals from Regulatory Bodies to Provide New Growth Opportunities

The different regulatory bodies across the globe are providing approval for various treatment solutions for COPD to aid patients suffering from uncontrolled COPD. In September 2024, the Medicines and Healthcare Products Agency (MHRA) authorized the usage of Dupilumab for treating uncontrolled COPD in the U.K. Dupilumab, a monoclonal antibody that inhibits the signaling of the interleukin-13 (IL13) and interleukin-4 (IL4) pathway, reduces type 2 inflammation observed in approximately 30-40% of patients with COPD. After receiving positive results from phase III clinical trials, the regulatory body has granted marketing authorization for subcutaneous injections as an add-on for maintenance treatment in adults with uncontrolled COPD.

Additionally, regulatory bodies increasingly provide accelerated approvals for novel treatment devices, drugs, and combination therapies to ensure patient access to advanced treatment solutions, driving innovation and positively influencing the market's expansion. Such approvals are essential as they aid in validating the efficacy and safety of the treatment solutions while fostering competition and allowing companies to introduce novel products.

Rising Research and Development Activities Support Market Expansion

The growing emphasis on research activities to bolster the availability of treatment solutions essential for treating COPD is a major global chronic obstructive pulmonary disease (COPD) treatment market driver. As the disease continues to impact millions across the globe, investments in research and development activities are rising to ensure the availability of effective treatment options. The multifaced research and development initiatives are targeting the development of innovative drugs, personalized medicines, and advanced inhalation devices to play a transformative role in managing COPD. For instance, in February 2024, ReAlta Life Sciences, Inc. initiated enrollment for the Phase II clinical trial of the RLS-0071 drug targeting acute exacerbations of COPD. The placebo-controlled, randomized, and double-blind trial assessed the pharmacokinetics, safety, efficacy, and pharmacokinetic-pharmacodynamic links of RLS-0071.

Additionally, the increasing collaborations between research institutions, healthcare providers, and pharmaceutical companies to address the complexities of COPD also provide lucrative growth opportunities to the market. Such partnerships and collaborations ensure cross-sector expertise sharing and support the development of advanced treatment solutions.

Hospital Pharmacies Account for Significant Market Share

Hospital pharmacies account for a significant share of the market owing to a wide range of factors, such as the unique dynamics of hospital settings and complex requirements for effective management of the condition. These pharmacies are essential for providing direct patient care to manage chronic health conditions such as COPD effectively. Pharmacists in these settings possess specialized knowledge and training in various respiratory medications, including combination therapies, corticosteroids, and bronchodilators. Furthermore, hospital pharmacies are equipped with a wide range of specialized formulations and advanced therapeutics which are often unavailable in retail pharmacies.

Additionally, hospital pharmacies across the globe are deploying technologically advanced solutions to facilitate efficient, safe, and accurate dispensing and management of drugs. As per the 2023 American Society of Health-System Pharmacists (ASHP) National Survey of Pharmacy Practice in Hospital Settings: Operations and Technology, approximately 73.6% of the hospitals surveyed utilize machine-readable coding for verifying doses during dispensing. Such efforts are also bolstering the segment's expansion.

North America is Anticipated to Hold a Major Market Share Over the Forecast Period

The expansion of the North America chronic obstructive pulmonary disease (COPD) treatment market can be attributed to the high acceptance and accessibility of novel diagnostic and treatment options and the strong presence of leading pharmaceutical companies in the region. Due to the rising prevalence of the condition in the region, the demand for effective treatment and management solutions is rising. According to the estimates of the Canadian Lung Association, over 2 million Canadians are affected by COPD, and it is one of the leading causes of hospitalization in Canada. The institute also estimates that there are approximately 1 million undiagnosed COPD population in the country.

The presence of different organizations, such as the American Association for Respiratory Care (AARC), that are dedicated to increasing awareness about lung health and treatment options available for various respiratory diseases, is also supporting the market's expansion. Furthermore, the strong presence of public and private healthcare systems in countries such as Canada and the United States is ensuring the affordability of COPD medication due to the widespread insurance coverage, bolstering the market's growth in North America.

Future Market Scenario (2024-2031F)

As per the global chronic obstructive pulmonary disease (COPD) treatment market analysis, the market is expected to witness significant growth in the coming years owing to the increasing efforts of the leading pharmaceutical companies to bolster the availability of novel therapies and the increasing prevalence of COPD. According to estimates from a modeling study published in the JAMA Network of the American Medical Association, by 2050, a relative growth of 23% in the number of patients with COPD will be witnessed compared to 2020.

Additionally, increasing government support and healthcare policy reforms across different regions are also expected to aid in addressing the cost-related challenges associated with COPD treatment, boosting patient access to the different treatment solutions. Innovative healthcare approaches, including precision medicine and digital healthcare solutions, are also anticipated to play a crucial role in COPD management and aid healthcare professionals in providing more effective and personalized treatment options. With the rise in investments in healthcare research and growing emphasis on developing innovative therapeutic solutions, the global chronic obstructive pulmonary disease (COPD) treatment market is expected to rapidly expand and aid patients in effectively managing the condition and improving their quality of life.

Key Players Landscape and Outlook

Key market players are actively investing in developing and introducing novel products in the market to aid patients suffering from COPD to manage the condition effectively. With the help of fast-track and breakthrough therapy designations for novel maintenance treatments for COPD, various regulatory bodies support such efforts. For instance, in August 2024, the Food and Drug Administration (FDA) granted breakthrough therapy designation as an add-on treatment for patients suffering from very severe to moderate COPD with a high blood count of eosinophils to AstraZeneca PLC and Amgen Inc.'s Tezspire. The primary intent of the breakthrough therapy designation is to provide interactive communications and timely advice to aid sponsors in conducting and designing drug development programs efficiently.

Similarly, in September 2024, Regeneron Pharmaceuticals, Inc. and Sanofi S.A.'s drug for treating COPD received approval from the FDA. Dupixent, the first biologic medicine approved in the United States for treating COPD, showed a 30% reduction in the annualized rate of COPD in a pair of Phase 3 studies. The drug had previously been approved for treating other conditions, such as asthma and atopic dermatitis. After receiving approval from the regulatory body, both companies witnessed a spike in their shares.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Type
    • 4.2.1.1. Emphysema
    • 4.2.1.2. Chronic Bronchitis
  • 4.2.2. By Drug Class
    • 4.2.2.1. Combination Therapy
    • 4.2.2.2. Bronchodilators
    • 4.2.2.3. Corticosteroids
    • 4.2.2.4. Phosphodiesterase Type 4 Inhibitor
    • 4.2.2.5. Mucokinetics
    • 4.2.2.6. Others
  • 4.2.3. By Distribution Channel
    • 4.2.3.1. Hospital Pharmacies
    • 4.2.3.2. Retail Pharmacies
    • 4.2.3.3. Online Pharmacies
  • 4.2.4. By Region
    • 4.2.4.1. North America
    • 4.2.4.2. Europe
    • 4.2.4.3. Asia-Pacific
    • 4.2.4.4. South America
    • 4.2.4.5. Middle East and Africa
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Distribution Channel
  • 4.3.4. By Region

5. North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Emphysema
    • 5.2.1.2. Chronic Bronchitis
  • 5.2.2. By Drug Class
    • 5.2.2.1. Combination Therapy
    • 5.2.2.2. Bronchodilators
    • 5.2.2.3. Corticosteroids
    • 5.2.2.4. Phosphodiesterase Type 4 Inhibitor
    • 5.2.2.5. Mucokinetics
    • 5.2.2.6. Others
  • 5.2.3. By Distribution Channel
    • 5.2.3.1. Hospital Pharmacies
    • 5.2.3.2. Retail Pharmacies
    • 5.2.3.3. Online Pharmacies
  • 5.2.4. By Country Share
    • 5.2.4.1. United States
    • 5.2.4.2. Canada
    • 5.2.4.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Type
        • 5.3.1.2.1.1. Emphysema
        • 5.3.1.2.1.2. Chronic Bronchitis
      • 5.3.1.2.2. By Drug Class
        • 5.3.1.2.2.1. Combination Therapy
        • 5.3.1.2.2.2. Bronchodilators
        • 5.3.1.2.2.3. Corticosteroids
        • 5.3.1.2.2.4. Phosphodiesterase Type 4 Inhibitor
        • 5.3.1.2.2.5. Mucokinetics
        • 5.3.1.2.2.6. Others
      • 5.3.1.2.3. By Distribution Channel
        • 5.3.1.2.3.1. Hospital Pharmacies
        • 5.3.1.2.3.2. Retail Pharmacies
        • 5.3.1.2.3.3. Online Pharmacies
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Clinical Trials
• 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. AstraZeneca PLC
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. Pfizer Inc.
  • 20.3.3. Teva Pharmaceutical Industries Ltd.
  • 20.3.4. Novartis AG
  • 20.3.5. F. Hoffmann-La Roche Ltd
  • 20.3.6. Boehringer Ingelheim International GmbH
  • 20.3.7. Sanofi S.A.
  • 20.3.8. GlaxoSmithKline plc
  • 20.3.9. Merck & Co., Inc.
  • 20.3.10. Almirall, S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer